Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer

International Journal of Gynecological Cancer

Volumn 9, Issue 5, 1999, Pages 365-372

  Von Gruenigen, V E ^a,b   O'Boyle, J D ^a,b   Coleman, R L ^a,b   Wilson, D ^c   Miller, D S ^a,b   Mathis, J M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Introgen Therapeutics Inc   (United States)

Author keywords

Adenovirus; Gene therapy; Ovarian cancer; p53

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL;

EID: 0032727205     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99040.x     Document Type: Article

References (41)

1. Bast RC Jr, Boyer CM, Jacobs I et al. Cell growth regulation on epithelial ovarian cancer. Cancer 1993;71: 1597-601.
2. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 1993;329: 1318-27.
3. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
4. Kohler MF, Marks JR, Wiseman RW et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
5. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 1994;6:96-105.
6. Santoso JT, Tang DC, Lane SB et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995;59:171-8.
7. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
8. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
9. Clayman GL, El-Nagger AK, Roght JA et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
10. Hamada K, Zhang WW, Alemany R, Roth JA, Wolf J, Mitchell M. Growth inhibition of human cervical cancer cells by the recombinant adenovirus-mediated transfer of wild-type p53 gene. Gynecol Oncol 1995;56:130-2.
11. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995;55:4210-3.
12. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 1998;69:197-204.
13. Kim J, Hwang ES, Kim JS, You EH, Lee SH, Lee JH. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse [In Process Citation]. Cancer Gene Ther 1999;6:172-8.
14. Zhang WW, Alemany R, Wang J, Koch P, Ordonex NB, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995;6:155-64.
15. Herz J, Gerard RD. Adenovirus-mediated transfer of low-density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993;90:2812-6.
16. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenoviral vectors. Circ Res 1993;72:1132-8.
17. Ragot T, Vincent N, Chafey R et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993;361:647-50.
18. Liu TJ, Zhang WW, Taylor DL, Roth JA, Geopfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the induction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54: 3662-7.
19. Jaffe HA, Danel C, Longenecker G et al. Adenovirus -mediated gene transfer and expression in normal rat liver. Nature Genet 1993;1:372-8.
20. Lagal La Salle G, Robert JJ, Bernard S, Ridoux V et al. Defective and non-defective adenovirus vectors for expression foreign genes in vitro and in vivo. Gene 1991;101:195-202.
21. Hamilton TC, Young RC, Louie KG et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intra abdominal carcinomatosis in mice. Cancer Res 1984;44:5286-90.
22. Nassander UK, Steerenberg PA, Poppe H et al. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res 1992;52:646-53.
23. Ozols RF, Louie KG, Plowman J et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987;36: 147-53.
24. Rotmensch J, Atoher RW, Schlenker R et al. The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy. Gynecol Oncol 1989;32:236-9.
25. Straubinger RM, Lopez NG, Debs RJ, Hong K, Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res 1988;48:5237-45.
26. Veatch AL, Carson LF, Ramakrishnan S. Phenotypic variations and differential migration of NIH. OVCAR-3 ovarian carcinoma cells isolated from athymic mice. Clin Exp Metastasis 1995;13:165-72.
27. Hamilton TC, Young RC, McKoy WM et al. Characterization of a human ovarian carcinoma cell line (NIH. OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-89.
28. Kohn EC, Liotta LA. L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 1990;82:54-60.
29. Kapiloff MS, Mathis JM, Lin CR, Nelson CA, Rosenfeld MG. Calcium/calmodulin-dependent protein kinase mediates a novel pathway for transcriptional regulation. Proc Natl Acad Sci USA 1991;88:3710-4.
30. Yamamoto RS, Kobayashi M, Plunkett JM, Masunaka IK, Orr SL, Granger GA. Production and detection of lymphotoxin in vitro: micro-assay for lymphotoxin. In: Yoshido T, ed. Investigation of Cell-Mediated Immunity. New York: Churchill Livingston, 1985: 126-34.
31. Levine AJ, Perry ME, Chang A et al. The role of the p53 tumor suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
32. Clinical protocols worldwide. Cancer Gene Ther 1996; 3:265-78.
33. Knoell DL, Yiu IM. Human gene therapy for hereditary diseases: a review of trials. Am J Health Syst Pharm 1998;55:899-904.
34. Nielsen LL, Gurnani M, Syed J et al. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Hum Gene Ther 1998;9:681-94.
35. Tang DC, Johnson SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther 1994;1:15-20.
36. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-23.
37. Mujoo K, Catino JJ, Maneval DC, Gutterman JU. Studies on the molecular mechanism of growth inhibition with p53 adenoviral construct in human ovarian cancer, Int J Gynecol Cancer 1998;8:233-41.
38. Cai DW, Mukhopadhyay T, Lui Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993;4:617-24.
39. Roth JA, Nguyen D, Lawrence DD et al. Retroviral-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996;2:985-91.
40. Roth JA, Swisher SG, Merritt JA et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998;25 (Suppl. 8):33-7.
41. Clinical trials. Oncology 1998;12 (8):1172-5.